BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 19041065)

  • 1. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
    Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
    Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reconstitution of protective immune responses against cytomegalovirus and varicella zoster virus does not require disease development in pediatric recipients of umbilical cord blood transplantation.
    Merindol N; Salem Fourati I; Brito RM; Grenier AJ; Charrier E; Cordeiro P; Caty M; Mezziani S; Malette B; Duval M; Alfieri C; Ovetchkine P; Le Deist F; Soudeyns H
    J Immunol; 2012 Nov; 189(10):5016-28. PubMed ID: 23034171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
    Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
    Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allotype analysis to distinguish the origin of varicella-zoster virus immunoglobulin G after allogeneic stem cell transplantation.
    Yamazaki R; Nakasone H; Tanaka Y; Sato M; Terasako K; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Ashizawa M; Machishima T; Kimura S; Kikuchi M; Okuda S; Kako S; Kanda J; Tanihara A; Nishida J; Kanda Y
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1013-20. PubMed ID: 23583826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-dose VZV vaccine.
    Levin MJ; Smith JG; Kaufhold RM; Barber D; Hayward AR; Chan CY; Chan IS; Li DJ; Wang W; Keller PM; Shaw A; Silber JL; Schlienger K; Chalikonda I; Vessey SJ; Caulfield MJ
    J Infect Dis; 2003 Nov; 188(9):1336-44. PubMed ID: 14593591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
    Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
    Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Live Attenuated High-Titer Varicella-Zoster Virus Vaccine in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Aoki T; Koh K; Kawano Y; Mori M; Arakawa Y; Kato M; Hanada R
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):771-775. PubMed ID: 26748161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varicella zoster reactivation after hematopoietic stem cell transplant in children is strongly correlated with leukemia treatment and suppression of host T-lymphocyte immunity.
    Vermont CL; Jol-van der Zijde EC; Hissink Muller P; Ball LM; Bredius RG; Vossen AC; Lankester AC
    Transpl Infect Dis; 2014 Apr; 16(2):188-94. PubMed ID: 24438482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients.
    van Besouw NM; Verjans GM; Zuijderwijk JM; Litjens NH; Osterhaus AD; Weimar W
    J Med Virol; 2012 Dec; 84(12):2018-25. PubMed ID: 23080511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the varicella zoster virus (VZV)-specific intra-ocular T-cell response in patients with VZV-induced uveitis.
    Milikan JC; Kuijpers RW; Baarsma GS; Osterhaus AD; Verjans GM
    Exp Eye Res; 2006 Jul; 83(1):69-75. PubMed ID: 16530754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Ma CK; Blyth E; Clancy L; Simms R; Burgess J; Brown R; Deo S; Micklethwaite KP; Gottlieb DJ
    Cytotherapy; 2015 Oct; 17(10):1406-20. PubMed ID: 26349000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine.
    Diaz PS; Smith S; Hunter E; Arvin AM
    J Immunol; 1989 Jan; 142(2):636-41. PubMed ID: 2536059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.
    Schub D; Janssen E; Leyking S; Sester U; Assmann G; Hennes P; Smola S; Vogt T; Rohrer T; Sester M; Schmidt T
    J Infect Dis; 2015 Feb; 211(4):600-12. PubMed ID: 25180236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varicella-zoster reactivation after allogeneic stem cell transplantation without routine prophylaxis--the incidence remains high.
    Blennow O; Fjaertoft G; Winiarski J; Ljungman P; Mattsson J; Remberger M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1646-9. PubMed ID: 24914821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between preexisting anti-varicella-zoster virus (VZV) antibody and clinical VZV reactivation in hematopoietic stem cell transplantation recipients.
    Onozawa M; Hashino S; Takahata M; Fujisawa F; Kawamura T; Nakagawa M; Kahata K; Kondo T; Ota S; Tanaka J; Imamura M; Asaka M
    J Clin Microbiol; 2006 Dec; 44(12):4441-3. PubMed ID: 17035500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination.
    Ludwig B; Kraus FB; Allwinn R; Keim S; Doerr HW; Buxbaum S
    Infection; 2006 Aug; 34(4):222-6. PubMed ID: 16896582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
    Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
    Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of viral antigens recognized by ocular infiltrating T cells from patients with varicella zoster virus-induced uveitis.
    Milikan JC; Kinchington PR; Baarsma GS; Kuijpers RW; Osterhaus AD; Verjans GM
    Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3689-97. PubMed ID: 17652740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants.
    Hata A; Asanuma H; Rinki M; Sharp M; Wong RM; Blume K; Arvin AM
    N Engl J Med; 2002 Jul; 347(1):26-34. PubMed ID: 12097537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.